|
1
|
Baccarani M, Deininger MW, Rosti G,
Hochhausd A, Soverini S, Apperley JF, Cervantes F, Clark RE, Cortes
JE, Guilhot F, et al: European leukemiaNet recommendations for the
management of chronic myeloid leukemia: 2013. Blood. 122:872–884.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Czechowska A, Poplawski T, Drzewoski J and
Blasiak J: Imatinib (STI571) induces DNA damage in
BCR/ABL-expressing leukemia cells but not in normal lymphocytes.
Chem Biol Interact. 152:139–150. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Jain P, Kantarjian H, Alattar ML, Jabbour
E, Sasaki K, Nogueras Gonzalez G, Dellasala S, Pierce S, Verstovsek
S, Wierda W, et al: Long-term molecular and cytogenetic response
and survival outcomes with imatinib 400 mg, imatinib 800 mg,
dasatinib and nilotinib in patients with chronic-phase chronic
myeloid leukaemia: Retrospective analysis of patient data from five
clinical trials. Lancet Haematol. 2:e118–e128. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Gorusu M, Benn P, Li Z and Fang M: On the
genesis and prognosis of variant translocations in chronic myeloid
leukemia. Cancer genet Cytogenet. 173:97–106. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Marzocchi G, Castagnetti F, Luatti S,
Baldazzi C, Stacchini M, Gugliotta G, Amabile M, Specchia G,
Sessarego M, Giussani U, et al: Variant Philadelphia
translocations: Molecular-cytogenetic characterization and
prognostic influence on frontline imatinib therapy, a GIMEMA
Working Party on CML analysis. Blood. 117:6793–6800. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Melo JV and Barnes DJ: Chronic myeloid
leukaemia as a model of disease evolution in human cancer. Nat Rev
Cancer. 7:441–453. 2007. View
Article : Google Scholar : PubMed/NCBI
|
|
7
|
Hehlmann R, Hochhaus A and Baccarani M:
Chronic myeloid leukaemia. Lancet. 370:342–350. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Skorski T: BCR/ABL, DNA damage and DNA
repair: Implications for new treatment concepts. Leuk Lymphoma.
49:610–614. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Brothman AR, Persons DL and Shaffer LG:
Nomenclature evolution: Changes in the ISCN from the 2005 to the
2009 edition. Cytogenet Genome Res. 127:1–4. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Al-Achkar W, Wafa A, Ali BY, Manvelyan M
and Liehr T: A rare chronic myeloid leukemia case with Philadelphia
chromosome, BCR-ABL e13a3 transcript and complex translocation
involving four different chromosomes. Oncol Lett. 1:797–800. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Al-Achkar W, Wafa A, Ikhtiar A and Liehr
T: Three-way Philadelphia translocation t(9;10;22)(q34;p11.2;q11.2)
as a secondary abnormality in an imatinib mesylate-resistant
chronic myeloid leukemia patient. Oncol Lett. 5:1656–1658. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Lee J, Kim DS, Lee HS, Choi SI and Cho YG:
A novel t(9;22;11) translocation involving 11q24 in a patient with
chronic myeloid leukemia: A case report. Oncol Lett. 13:1711–1713.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Cho SY, Kim SY, Jeon YL, Oh SH, Cho EH,
Lee WI, Cho KS and Park TS: A novel three-way Ph variant t(8;9;22)
in adult acute lymphoblastic leukemia. Ann Clin Lab Sci. 41:71–78.
2011.PubMed/NCBI
|
|
14
|
Huret JL: Complex translocations, simple
variant translocations and Ph-negative cases in chronic myelogenous
leukaemia. Hum Genet. 85:565–568. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Richebourg S, Eclache V, Perot C, Portnoi
MF, Van den Akker J, Terré C, Maareck O, Soenen V, Viguié F, Laï
JL, et al: Mechanisms of genesis of variant translocation in
chronic myeloid leukemia are not correlated with ABL1 or BCR
deletion status or response to imatinib therapy. Cancer Genet
Cytogenet. 182:95–102. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
El-Zimaity MM, Kantarjian H, Talpaz M,
O'Brien S, Giles F, Garcia-Manero G, Verstovsek S, Thomas D,
Ferrajoli A, Hayes K, et al: Results of imatinib mesylate therapy
in chronic myelogenous leukaemia with variant Philadelphia
chromosome. Br J Haematol. 125:187–195. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Baccarani M, Cortes J, Pane F,
Niederwieser D, Saglio G, Apperley J, Cervantes F, Deininger M,
Gratwohl A, Guilhot F, et al: Chronic myeloid leukemia: An update
of concepts and management recommendations of European Leukemia
Net. J Clin Oncol. 27:6041–6051. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Tan J, Cang S, Seiter K, Primanneni S,
Ahmed N, Mathews T and Liu D: t(3;9;22) 3-way chromosome
translocation in chronic myeloid leukemia is associated with poor
prognosis. Cancer Invest. 27:718–722. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Buda G, Orciuolo E, Galimberti S,
Benedetti E, Caracciolo F, Cervetti G, Carulli G, Papineschi F and
Petrini M: Complex translocation t(3;9;22)(q21;q34;q11) at
diagnosis is a negative prognostic index in chronic myeloid
leukemia. Leuk Res. 32:192–194. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Morrissey C, Martinez A, Zatyka M,
Agathanggelou A, Honorio S, Astuti D, Morgan NV, Moch H, Richards
FM, Kishida T, et al: Epigenetic inactivation of the RASSF1A 3p21.3
tumor suppressor gene in both clear cell and papillary renal cell
carcinoma. Cancer Res. 61:7277–7281. 2001.PubMed/NCBI
|
|
21
|
Hemminki A, Peltomäki P, Mecklin J,
Järvinen H, Salovaara R, Nyström-Lahti M, de la Chapelle A and
Aaltonen LA: Loss of the wild-type MLH1 gene is a feature of
hereditary nonpolyposis colorectal cancer. Nat Genet. 8:405–410.
1994. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Oh JJ, Razfar A, Delgado I, Reed RA,
Malkina A, Boctor B and Slamon DJ: 3p21.3 tumor suppressor gene
H37/Luca15/RBM5 inhibits growth of human lung cancer cells through
cell cycle arrest and apoptosis. Cancer Res. 66:3419–3427. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Shi G, Weh HJ, Martensen S, Seeger D and
Hossfeld DK: 3p21 is a recurrent treatment-related breakpoint in
myelodysplastic syndrome and acute myeloid leukemia. Cytogenet Cell
Genet. 74:295–299. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Johansson B, Billström R, Kristoffersson
U, Akerman M, Garwicz S, Ahlgren T, Malm C and Mitelman F: Deletion
of chromosome arm 3p in hematologic malignancies. Leukemia.
11:1207–1213. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Whang-peng J, Knutsen TA and Lee EC:
Dicentric Ph1 chromosome. J Natl Cancer Inst. 51:2009–2012. 1973.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Yamamoto K, Nagata K, Morita Y, Inagaki K
and Hamaguchi H: Isodicentric Philadelphia chromosome in acute
lymphoblastic leukemia with der (7;12)(q10;q10). Leuk Res.
31:713–718. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Becher R, Ohl S, Schaefer UW, Wendehorst
E, Quiskamp F, Mahmoud HK, Schüning F and Schmidt CG: Clonal
evolution with isodicentric Ph1 chromosome in Ph1-positive CML:
Karyotypic conversion after bone marrow transplantation. Blut.
48:247–250. 1984. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Kovacs G, Georgii A and Mainzer K: Three
isodicentric Philadelphia chromosomes in acute phase of chronic
myeloid leukemia: A case report. Cancer Genet Cytogenet. 20:29–33.
1986. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Pernice F, Squadrito G, Saitta A, Mazza G
and Musolino C: Isodicentric Philadelphia chromosome in accelerated
phase of chronic myeloid leukemia. Cancer Genet Cytogenet.
66:113–116. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Szych CM, Liesveld JL, Iqbal MA, Li L,
Siebert S, Asmus C, O'Malley J, Lee A and Wang N: Isodicentric
Philadelphia chromosomes in imatinib mesylate (Gleevec)-resistant
patients. Cancer Genet Cytogenet. 174:132–137. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Li Ming, Chua C, Tan YY, Chua SP, Ma HB,
Koay E, Li Min, Poon M, Liu TC and Gole L: Multiple copies of a
rare rearrangement of Philadelphia chromosome in a chronic myeloid
leukemia patient: A case report. Cancer Genet Cytogenet. 199:66–68.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Hochhaus A and Hughes T: Clinical
resistance to imatinib: Mechanisms and implications. Hematol Oncol
Clin North Am. 18:641–656. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Campbell LJ, Patsouris C, Rayeroux KC,
Somana K, Januszewicz EH and Szer J: BCR/ABL amplification in
chronic myelocytic leukemia blast crisis following imatinib
mesylate administration. Cancer Genet Cytogent. 139:30–33. 2002.
View Article : Google Scholar
|
|
34
|
Ikeda K, Harada-Shirado K, Matsumoto H,
Noji H, Ogawa K and Takeishi Y: Molecular response of e19a2
BCR-ABL1 Chronic myeloid leukemia with double Philadelphia
chromosome to Dasatinib. J Clin Oncol. 34:e130–e133. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Martin SE, Sausen M, Joseph A and Kingham
BF: Chronic myeloid leukemia with e19a2 atypical transcript: Early
imatinib resistance and complete response to dasatinib. Cancer
Genet Cytogenet. 201:133–134. 2010. View Article : Google Scholar : PubMed/NCBI
|
